Christiane Ahlers
Overview
Explore the profile of Christiane Ahlers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
86
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rossing P, Anker S, Filippatos G, Pitt B, Ruilope L, Billings L, et al.
Diabetes Obes Metab
. 2023 Jul;
25(10):2989-2998.
PMID: 37402696
Aim: To assess the effect of finerenone on the risk of cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes, with and without obesity. Materials...
2.
Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, et al.
Clin J Am Soc Nephrol
. 2023 Mar;
18(5):602-612.
PMID: 36927680
Background: Patients with stage 4 CKD and type 2 diabetes have limited treatment options to reduce their persistent cardiovascular and kidney risk. In Finerenone in Chronic Kidney Disease and Type...
3.
Bakris G, Ruilope L, Anker S, Filippatos G, Pitt B, Rossing P, et al.
Kidney Int
. 2022 Nov;
103(1):196-206.
PMID: 36367466
In FIDELITY, a prespecified pooled analysis of the FIDELIO-DKD and FIGARO-DKD studies, finerenone was found to improve cardiorenal outcomes in patients with type 2 diabetes, a urine albumin-to-creatinine ratio of...
4.
Pitt B, Agarwal R, Anker S, Ruilope L, Rossing P, Ahlers C, et al.
JAMA Netw Open
. 2022 Oct;
5(10):e2236123.
PMID: 36287567
Importance: Patients with chronic kidney disease and type 2 diabetes have a higher risk of developing pneumonia as well as an increased risk of severe COVID-19-associated adverse events and mortality....
5.
Frenz A, Ahlers C, Beckert V, Gerlinger C, Friede T
Eur J Contracept Reprod Health Care
. 2020 Dec;
26(1):48-57.
PMID: 33269954
Purpose: To develop a bleeding-pattern prediction model to inform counselling on amount and regularity of bleeding after levonorgestrel-releasing intrauterine system (LNG-IUS) placement. Materials And Methods: Fixed-cluster and regression-tree models were...
6.
Jensen J, Bitzer J, Nappi R, Ahlers C, Bannemerschult R, Parke S
Eur J Contracept Reprod Health Care
. 2020 Mar;
25(2):98-105.
PMID: 32162555
To evaluate differences in key outcomes between younger and older women receiving the oral contraceptive oestradiol valerate/dienogest (E2V/DNG). We conducted a pooled analysis of primary data from 12 studies of...
7.
Feltgen N, Ogura Y, Boscia F, Holz F, Korobelnik J, Brown D, et al.
Ophthalmol Retina
. 2019 Jul;
3(7):553-560.
PMID: 31277796
Purpose: To evaluate the impact of baseline retinal capillary nonperfusion (RNP) and macular retinal capillary nonperfusion (MNP) status on outcomes at week 24 (W24). Design: Post hoc analyses of 2...
8.
Beckert V, Ahlers C, Frenz A, Gerlinger C, Bannemerschult R, Lukkari-Lax E
Eur J Contracept Reprod Health Care
. 2019 Jun;
24(4):251-259.
PMID: 31223042
The aim of the study was to provide an additional, detailed description of early bleeding patterns with the 19.5 mg levonorgestrel-releasing intrauterine system (LNG-IUS). We conducted a pooled analysis of...
9.
Techatraisak K, Hestiantoro A, Ruey S, Banal-Silao M, Kim M, Seong S, et al.
BMC Womens Health
. 2019 May;
19(1):68.
PMID: 31096979
Background: Dienogest has been shown to substantially improve endometriosis-associated symptoms such as debilitating chronic pelvic pain, and in turn, health-related quality of life (HRQoL). To date, there is no data...
10.
Lanzetta P, Cruess A, Cohen S, Slakter J, Katz T, Sowade O, et al.
Acta Ophthalmol
. 2018 Apr;
96(8):e911-e918.
PMID: 29659183
Purpose: Identify predictors for response to anti-vascular endothelial growth factor (VEGF) therapy in patients with neovascular (wet) age-related macular degeneration (nAMD). Methods: Retrospective, post hoc analysis of VIEW 1/2. Patients...